| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.57 | 27.6% | 65.0% |
| Total Income | 1.57 | 27.6% | 65.0% |
| Expenditure | 307.80 | 7.2% | 11.1% |
| PBT | -159.04 | 40.9% | 29.1% |
| Net Profit | -113.52 | 49.2% | 50.7% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.17 | 48.5% | 45.2% |
Roivant Reports Q2 2025 Results; Cash Position at $4.4 Billion
04 May 2026 · 4 May, 7:29 am
Summary
Roivant Sciences Ltd. reported its financial results for the second quarter ended September 30, 2025. The company's consolidated cash, cash equivalents, restricted cash, and marketable securities totaled $4.4 billion. Research and development expenses increased to $164.6 million, while general and administrative expenses decreased to $143.1 million. The loss from continuing operations, net of tax, was $166.0 million for the quarter.
Key Highlights
- 1
Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billion as of September 30, 2025, supporting cash runway into profitability.
- 2
Research and development expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025.
- 3
Non-GAAP R&D expenses were $152.9 million for the three months ended September 30, 2025.
- 4
General and administrative expenses decreased by $59.8 million to $143.1 million for the three months ended September 30, 2025.
- 5
Non-GAAP G&A expenses were $72.1 million for the three months ended September 30, 2025.
- 6
Loss from continuing operations, net of tax was $166.0 million for the three months ended September 30, 2025.
- 7
Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM).
Management Comments
Matt Gline
This quarter unquestionably represents a moment of transformation for Roivant, with the brepocitinib data in DM putting us on a new and exciting trajectory. This is further supported by Immunovant's remission data in Graves' disease, and by strong continued execution and progress across the board. “We look forward to sharing more about our progress and next chapter at our investor day in December.”
Informational and educational content only. Not investment advice.